News & Insights

Audience Survey: Where do you think the greatest opportunity for pharma and MedTech collaboration lies?  Audience reply: Early Diagnosis AND Drug/Device combos (it was the only tie at TCT!)

AstraZeneca’s Mikhail Kosibord offered insights about how AI is shaping the pharma side of medicine:  Using obesity management as an example, transferring from a “one-size-fits-all” approach to a personalized, patient-bespoke approach is not only possible, but offers improved results.

Integrating technology into pharma clinical trials means better data capture and interpretation and interpolation.  Mikhail shared how data capture using AI can mean shorter trials (both in duration and size) with more meaningful results and deeper understanding.

Finally, he covered how technology can disrupt the standard of care in ways that offer greater access to care globally.

Molecular Biologist and co-founder of Scribe Therapeutics Benjamin Oakes took to the podium after Mikhail to drive home the notion of changing to PREVENTATIVE care in the ultimate fashion.  He and his team at Molecular Therapeutics seek ways to incorporate gene therapy into medical device work.

Sadly, as Mikhail said, pharma companies like AstraZeneca are not investing in prevention – but there is hope.  He feels that in another 15-20 years, that will change.  To make this happen, a fundamental shift is required.